Journal: Nature Medicine

Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

doi: 10.1038/s41591-026-04449-9

Figure Lengend Snippet: Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

Article Snippet: Antibodies for the TCR/DC panel included TCRγδ Vio Blue (Miltenyi Biotec, cat. no.1 30-119-619), TCRαβ FITC (Miltenyi Biotec, cat. no. 130-113-538), CD83 PE (Miltenyi Biotec, cat. no. 130-110-503), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141) and CD45 APC (Miltenyi Biotec, cat. no. 130-110-633).

Techniques: Enzyme-linked Immunospot, Whisker Assay

Journal: Nature Medicine

Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

doi: 10.1038/s41591-026-04449-9

Figure Lengend Snippet: a-f ) Longitudinal tracking of product‑derived clonotypes for assayed participants who received infusion of specific TAA‑T products. Time points corresponding to disease progression (if applicable) are indicated by the downward black arrow. Abbreviations : “Pre” = prior to first TAA‑T cell infusion; I = infusion; W = week; M = month. ( a ) P09 (Arm B). b ) P12 (Arm B). c ) P10 (Arm A). d ) P20 (Arm B). e ) P26 (Arm B). f ) P35 (Arm B). g ) Global TCR Repertoire Dynamics (Arms B/C) – Simpson Clonality. Color coding indicates participants with increases in Simpson’s Clonality relative to baseline. Baseline PBMC samples are from the pre-infusion time point for Arm B. For Arm C patients, post lymphodepletion, pre-infusion samples were not available for all patients so week 1 post-infusion was first available time point sampled longitudinally.

Article Snippet: Antibodies for the TCR/DC panel included TCRγδ Vio Blue (Miltenyi Biotec, cat. no.1 30-119-619), TCRαβ FITC (Miltenyi Biotec, cat. no. 130-113-538), CD83 PE (Miltenyi Biotec, cat. no. 130-110-503), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141) and CD45 APC (Miltenyi Biotec, cat. no. 130-110-633).

Techniques: Biomarker Discovery

Journal: Biology

Article Title: Development of Replicon Cell Pools Bearing a Flavivirus RNA Replicon as a Source of HIV-1 Gag-Pol for Lentiviral Vector Production

doi: 10.3390/biology15110848

Figure Lengend Snippet: Characterization of a CAR-T cell product generated using LV/CAR vector produced from RCP cells. ( a ) Representative flow cytometry plots showing the gating strategy used for counting CAR + cells (debris exclusion, CD45 + leukocytes, viable cells, CD3 + T cells, and CAR + subset within CD3 + cells). ( b ) Summary of cell product composition after T-cell selection and transduction, including cell subsets, markers, event counts, and relative frequencies.

Article Snippet: The CAR-T cell product was analyzed by flow cytometry using the following antibody panel from Miltenyi Biotec: CD3-FITC (130-113-138), CD4-VioGreen (130-113-221), CD8-APC-Vio770 (130-113-155), CD14-APC (130-113-143), CD45-VioBlue (130-113-122), biotinylated CD19 CAR Detection Reagent (130-129-550), anti-biotin- phycoerythrin (PE)-conjugated antibody (130-113-291).

Techniques: Generated, Plasmid Preparation, Produced, Flow Cytometry, Selection, Transduction

Journal: International Journal of Molecular Sciences

Article Title: Proinflammatory Cytokine Preconditioning Enhances the Therapeutic Potency of Different Types of MSCs in Inflammation

doi: 10.3390/ijms27094090

Figure Lengend Snippet: Cytomix increased the expression of immunomodulatory markers on BM-MSCs, iMSCs WT and iMSCs B2M KO. The gating strategy is shown in . ( A ) Histogram charts of the expression of the immunomodulatory markers on BM-MSCs, iMSCs WT and iMSCs B2M KO. ( B – H ) Cytomix significantly increased the expression levels of HLA-ABC on BM-MSCs and iMSCs WT, HLA-DR on BM-MSCs, CD54 on all types of MSCs, CD200 on iMSCs WT, CD119 and CD120b on BM-MSCs, and CD274 on iMSCs WT and iMSCs B2M KO. Representative results of three independent experiments are shown. Results are shown as mean ± SD ( n = 3 in each group) and analysed by two-way ANOVA with Šídák’s multiple comparisons test or Tukey’s multiple comparisons test. */**/***/**** represent comparisons of naïve vs. Cytomix in each type of MSC; $/$$$/$$$$ represent comparisons of BM-MSCs vs. iMSCs WT vs. iMSCs B2M KO in the naïve group; ##/###/#### represent comparisons of BM-MSCs vs. iMSCs WT vs. iMSCs B2M KO in the Cytomix group with significance levels of p < 0.05/0.01/0.001/0.0001, respectively. Nd represents not detectable.

Article Snippet: The cells were centrifuged at 300× g for 5 min and resuspended in 100 μL FACS buffer containing anti-human HLA-ABC-VioGreen, HLA-DR-VioBlue, CD54-APC, CD274-PE-Vio ® 615, CD119-FITC (Cat# 130-120-436, 130-111-794, 130-121-342, 130-122-811, 130-099-931; Miltenyi Biotec, Bergisch Gladbach, Germany), CD120b-PE and CD200-PE-CY7 antibodies (Cat# 358403, 399805; BioLegend, San Diego, CA, USA).

Techniques: Expressing